Biotech · Public company · Rochester, NY, US
Vaccinex, Inc.
Ticker VCNX · SEC CIK 0001205922
Track this companyFree. Adds Vaccinex, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials93 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline5
- Avelumab and PepinemabPhase 2 · Metastatic Pancreatic AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PepinemabPhase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- pepinemab + pembrolizumabPhase 2 · Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)ClinicalTrials.gov · fetched Nov 12, 2026
- VX15/2503Phase 2 · Huntington's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- VX15/2503 + avelumabPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic AdenocarcinomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 10, 2022ClinicalTrials.gov NCT05102721 · fetched Nov 12, 2026
- Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast CancerPHASE1 · SUSPENDED · started May 31, 2022ClinicalTrials.gov NCT05378464 · fetched Nov 12, 2026
- Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckPHASE1_PHASE2 · COMPLETED · started Aug 9, 2021ClinicalTrials.gov NCT04815720 · fetched Nov 12, 2026
- SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)PHASE1_PHASE2 · COMPLETED · started Jul 22, 2021ClinicalTrials.gov NCT04381468 · fetched Nov 12, 2026
- VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 13, 2018ClinicalTrials.gov NCT03769155 · fetched Nov 12, 2026
- VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 1, 2018ClinicalTrials.gov NCT03690986 · fetched Nov 12, 2026
- VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerPHASE1 · COMPLETED · started Dec 15, 2017ClinicalTrials.gov NCT03373188 · fetched Nov 12, 2026
- VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung CancerPHASE1_PHASE2 · COMPLETED · started Oct 5, 2017ClinicalTrials.gov NCT03268057 · fetched Nov 12, 2026
- A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of PepiPHASE2 · COMPLETED · started Jul 1, 2015ClinicalTrials.gov NCT02481674 · fetched Nov 12, 2026
SEC filings6
- 10-K · 10-KSEC EDGAR · filed Apr 15, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 19, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 7, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 17, 2024 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 14, 2024 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 14, 2024 · fetched Nov 12, 2026